Every letter we have printed
Page 40 of 77 of this archive, newest first.
On “The limits of mechanism: why receptor data will not tell you who responds” — Pharmacology, 19 Mar 2025
Your piece states that moving the injection day does not change total exposure, and I accept the arithmetic, but I want to record that it changed my experience considerably. I moved from Monday morning to Thursday evening and the two worst days now fall on a weekend. The drug is doing the same thing; my week is not.
— T. Brannon, Boise, ID
This is exactly the distinction we were trying to draw and evidently drew badly. Total exposure is unchanged; the phase relationship between peak concentration and your working week is not. We have added a sentence to that effect.
On “The submitted sample: the weakest link in the whole system” — The Supply Chain, 18 Mar 2025
Your suggestion that laboratories publish the fact of a submission while keeping the result confidential is the first proposal I have read in this area that a laboratory could actually implement without breaching a client obligation. I have raised it internally.
— N. Villaseñor, Guadalajara
We would be glad to report the outcome either way, including if the answer is no and the reason is commercial. The proposal is only useful if somebody adopts it, and a published refusal is more informative than silence.
On “The submitted sample: the weakest link in the whole system” — The Supply Chain, 18 Mar 2025
You disclose that two of these services advertise with you and then spend four thousand words on structural criticism of the sector they operate in. I cannot decide whether that is admirable independence or an elaborate way of appearing independent. Probably the former. I wanted to say that I noticed the question.
— N. Zangwill, Manchester
So do we, every time this department writes about the sector. The only answers we have are procedural: the disclosure, the standards desk edit, the consulting prohibition on the writer, and the practice of printing objections like yours unedited.
On “The submitted sample: the weakest link in the whole system” — The Supply Chain, 18 Mar 2025
As a buyer I found the section on who chose the vial genuinely clarifying and slightly deflating. I have been treating vendor-published reports as equivalent to my own submissions for two years, and on your account they are not equivalent by an amount that cannot be measured.
— P. Havlíček, Brno
That is the correct reading, and the unmeasurable part is the honest part. We would add only that vendor-published reports are not worthless — a vendor willing to commission testing at all is behaving better than one that will not — they are simply weaker in a specific way.
On “The submitted sample: the weakest link in the whole system” — The Supply Chain, 18 Mar 2025
Your selection-effect model assumes a supplier publishes results above a fixed threshold. Real behaviour is surely more complicated: a supplier might publish a poor result on a batch it has withdrawn, or publish everything for a period to establish credibility and then stop. The arithmetic is fine and the behavioural assumption is a cartoon.
— B. Achterberg, Utrecht
Agreed, and the figure caption now says illustrative arithmetic rather than model. The point survives the simplification, which is that a small amount of selection produces a large apparent effect, but we should not have dressed a demonstration as an estimate.
On “Tolerability is the ceiling, and the ceiling is personal” — Patient Notes, 17 Mar 2025
You note that symptom burden does not predict weight outcome. This is the single most useful sentence I have read about this treatment. I spent four months believing that feeling well meant it was not working and considered increasing my dose on that basis alone.
— L. Kowalski, Gdańsk
The folk model that suffering indexes efficacy is widespread and the published analyses do not support it. It is also actively harmful when it drives escalation, which is why we gave it a line in the closing section rather than burying it in the tables.
On “Tolerability is the ceiling, and the ceiling is personal” — Patient Notes, 17 Mar 2025
Your incidence tables are from the licensed products. I use compounded material at a concentration that does not match any pen. Are the figures transferable at all?
— B. Osei-Bonsu, Kumasi
The mechanism transfers; the incidence figures transfer only to the extent that your actual exposure matches the trial exposure, which is unknown unless the content has been measured. That is not evasion. It is the reason we argue for peptide content as a standard reported field rather than purity alone.
On “Tolerability is the ceiling, and the ceiling is personal” — Patient Notes, 17 Mar 2025
A small point of precision. You use "gastroparesis" in the tag list and then spend a paragraph saying it is not a synonym for drug-induced emptying delay. That is a slightly awkward position to hold.
— I. Mukherjee, Kolkata
It is, and it is a compromise with how readers search. The tag exists because that is the word people use; the glossary exists because it is the wrong one. We would rather be findable and then precise than precise and unread.
On “Tolerability is the ceiling, and the ceiling is personal” — Patient Notes, 17 Mar 2025
Nothing in your file addresses the social dimension, which for me was worse than the nausea. Six months of declining invitations to meals, and explaining to family why I was not eating. The tables do not have a row for that.
— M. Halim, Kuala Lumpur
On “Tolerability is the ceiling, and the ceiling is personal” — Patient Notes, 17 Mar 2025
You report the STEP 1 nausea figure as approximately forty-four per cent. The publication gives 44.2 per cent. Given how much of your argument rests on precision about what these numbers mean, the rounding sits oddly.
— E. Vandenberghe, Ghent
Deliberate, and worth explaining. A tenth of a percentage point on a figure with a confidence interval several points wide implies a precision the data does not have. We give the exact figure in the tables and round in prose, which is a convention we should have stated rather than left to be noticed.
On “Not everybody regains at the same rate, and nobody knows why” — Clinical Trials, 16 Mar 2025
Your piece describes tapering as pharmacologically pointless and then spends three paragraphs making a case for it. Pick one.
— S. Lindgren, Uppsala
Both, we think, and deliberately. There is no pharmacological rationale, because there is no withdrawal syndrome and a week-long half-life produces its own decline. There is a behavioural rationale, which is different in kind and untested. Our objection is to tapers advocated in pharmacological language, not to the practice.
On “Not everybody regains at the same rate, and nobody knows why” — Clinical Trials, 16 Mar 2025
I lost access for eleven weeks during the shortage, restarted at the dose I had been on because nobody told me otherwise, and spent a fortnight unable to keep food down. I had been on that dose for seven months without difficulty. Reading your resumption section was the first time anybody explained it.
— T. Brannon, Boise, ID
It is entirely predictable from the label and the pharmacokinetics, and the failure to communicate it during the shortage period was systemic rather than individual. We are sorry it reached you this way and we are glad it reached you.
On “Not everybody regains at the same rate, and nobody knows why” — Clinical Trials, 16 Mar 2025
As a prescriber I would push back on your framing of the maintenance gap. We are not practising without evidence; we are practising on pharmacological inference, which is what clinicians do in every field where the trial has not been run. Calling it unevidenced makes reasonable practice sound reckless.
— L. Nyoni, Harare
A fair objection and we have adjusted the wording. Our intention was to locate the absence with the people who could have funded the trial rather than with the clinicians managing without it, and on rereading the original paragraph did not achieve that.
On “How a correct calculation becomes a wrong dose” — Explainers, 13 Mar 2025
Your needle-length section says four millimetres is adequate for all adults, which contradicts what I was told by a nurse who insisted on half an inch because of my weight. Which is right?
— H. Nakagawa, Fukuoka
The published recommendations are with us, and the reason is that skin thickness varies remarkably little with body mass while subcutaneous fat varies enormously. A longer needle in a heavier person is not more likely to reach the right layer; it is only more likely to go past it in a thinner limb. We would put the ultrasound measurement studies in front of your nurse rather than argue from authority.
On “Chain of custody, and where it begins” — The Ledger, 12 Mar 2025
As a buyer I found the section on who chose the vial genuinely clarifying and slightly deflating. I have been treating vendor-published reports as equivalent to my own submissions for two years, and on your account they are not equivalent by an amount that cannot be measured.
— P. Sandoval, Albuquerque, NM
That is the correct reading, and the unmeasurable part is the honest part. We would add only that vendor-published reports are not worthless — a vendor willing to commission testing at all is behaving better than one that will not — they are simply weaker in a specific way.
On “Chain of custody, and where it begins” — The Ledger, 12 Mar 2025
Your selection-effect model assumes a supplier publishes results above a fixed threshold. Real behaviour is surely more complicated: a supplier might publish a poor result on a batch it has withdrawn, or publish everything for a period to establish credibility and then stop. The arithmetic is fine and the behavioural assumption is a cartoon.
— Q. Delacroix, Montréal, QC
Agreed, and the figure caption now says illustrative arithmetic rather than model. The point survives the simplification, which is that a small amount of selection produces a large apparent effect, but we should not have dressed a demonstration as an estimate.
On “Chain of custody, and where it begins” — The Ledger, 12 Mar 2025
Your suggestion that laboratories publish the fact of a submission while keeping the result confidential is the first proposal I have read in this area that a laboratory could actually implement without breaching a client obligation. I have raised it internally.
— S. Weatherall, Newcastle, NSW
We would be glad to report the outcome either way, including if the answer is no and the reason is commercial. The proposal is only useful if somebody adopts it, and a published refusal is more informative than silence.
On “Chain of custody, and where it begins” — The Ledger, 12 Mar 2025
You disclose that two of these services advertise with you and then spend four thousand words on structural criticism of the sector they operate in. I cannot decide whether that is admirable independence or an elaborate way of appearing independent. Probably the former. I wanted to say that I noticed the question.
— T. Aoyama, Nagoya
So do we, every time this department writes about the sector. The only answers we have are procedural: the disclosure, the standards desk edit, the consulting prohibition on the writer, and the practice of printing objections like yours unedited.
On “Chain of custody, and where it begins” — The Ledger, 12 Mar 2025
I submitted a vial to one of these services last year, got a result three points below what the vendor advertised, and did not know what to do with it. Your article explains why: I had one measurement on one vial, no method comparison, and no way to know if my vial was representative. I still do not know what to do with it, but I understand the shape of not knowing.
— M. Guðmundsdóttir, Reykjavík
That is a better summary of this article’s practical content than our own closing paragraphs. The one thing we would add is that your result is worth publishing wherever you can, because buyer-submitted results are the scarcest and most informative category in the entire corpus.
On “Delayed emptying explains some of this, and not all of it” — Explainers, 9 Mar 2025
Nothing in your file addresses the social dimension, which for me was worse than the nausea. Six months of declining invitations to meals, and explaining to family why I was not eating. The tables do not have a row for that.
— T. Blakemore, Hull
On “Delayed emptying explains some of this, and not all of it” — Explainers, 9 Mar 2025
A small point of precision. You use "gastroparesis" in the tag list and then spend a paragraph saying it is not a synonym for drug-induced emptying delay. That is a slightly awkward position to hold.
— M. Guðmundsdóttir, Reykjavík
It is, and it is a compromise with how readers search. The tag exists because that is the word people use; the glossary exists because it is the wrong one. We would rather be findable and then precise than precise and unread.
On “Delayed emptying explains some of this, and not all of it” — Explainers, 9 Mar 2025
Your incidence tables are from the licensed products. I use compounded material at a concentration that does not match any pen. Are the figures transferable at all?
— M. Suárez, Montevideo
The mechanism transfers; the incidence figures transfer only to the extent that your actual exposure matches the trial exposure, which is unknown unless the content has been measured. That is not evasion. It is the reason we argue for peptide content as a standard reported field rather than purity alone.
On “Delayed emptying explains some of this, and not all of it” — Explainers, 9 Mar 2025
You note that symptom burden does not predict weight outcome. This is the single most useful sentence I have read about this treatment. I spent four months believing that feeling well meant it was not working and considered increasing my dose on that basis alone.
— A. Lindholm, Gothenburg
The folk model that suffering indexes efficacy is widespread and the published analyses do not support it. It is also actively harmful when it drives escalation, which is why we gave it a line in the closing section rather than burying it in the tables.
On “Holding a dose is a decision, not a failure” — Pharmacology, 9 Mar 2025
A small thing. You give the semaglutide diabetes ladder as ending at 2.0 mg and the weight ladder at 2.4 mg, without explaining why the same molecule has two ceilings for two indications. It looks arbitrary and I suspect it is not.
— R. Devaney, Ballarat, VIC
It is not arbitrary — the two maxima come from separate dose-selection programmes with different primary endpoints, and 2.0 mg was established against 1.0 mg in a dedicated glycaemic comparison. We have added a clause. The underlying point, that indication shapes the ladder as much as the molecule does, is worth more space than we gave it.
On “Holding a dose is a decision, not a failure” — Pharmacology, 9 Mar 2025
I had a nine-week gap last year because my supplier stopped answering messages. Nobody in any clinical setting I dealt with treated that as a pharmacological event. Your framing of supply interruption as a dosing decision is the first time I have seen it written down.
— W. Stroud, Chattanooga, TN
On “Holding a dose is a decision, not a failure” — Pharmacology, 9 Mar 2025
You describe the plateau as an energy-balance event and dismiss receptor desensitisation. Is there not a third possibility — that adherence quietly falls off at around a year and the plateau is partly a behavioural artefact of the trial rather than a physiological one?
— B. Wojciechowski, Kraków
There is, and it is a better objection than the desensitisation argument. Adherence does decline over the second year of the long programmes, and the treatment-policy analyses absorb that decline into the mean. We should have said that the plateau is very likely a composite of energy balance and falling adherence, in proportions the published analyses do not separate cleanly.
On “A tested vial is evidence about a vial” — The Ledger, 8 Mar 2025
As a buyer I found the section on who chose the vial genuinely clarifying and slightly deflating. I have been treating vendor-published reports as equivalent to my own submissions for two years, and on your account they are not equivalent by an amount that cannot be measured.
— N. Fairweather, Hamilton
That is the correct reading, and the unmeasurable part is the honest part. We would add only that vendor-published reports are not worthless — a vendor willing to commission testing at all is behaving better than one that will not — they are simply weaker in a specific way.
On “A tested vial is evidence about a vial” — The Ledger, 8 Mar 2025
Your selection-effect model assumes a supplier publishes results above a fixed threshold. Real behaviour is surely more complicated: a supplier might publish a poor result on a batch it has withdrawn, or publish everything for a period to establish credibility and then stop. The arithmetic is fine and the behavioural assumption is a cartoon.
— M. Karlsen, Kristiansand
Agreed, and the figure caption now says illustrative arithmetic rather than model. The point survives the simplification, which is that a small amount of selection produces a large apparent effect, but we should not have dressed a demonstration as an estimate.
On “Which results are findings and which are consequences of the weight loss” — Patient Notes, 7 Mar 2025
As a biomedical scientist I would add one point to your reference-interval section: many laboratories do not derive their own intervals at all. They adopt the manufacturer interval for the platform, which was established in a population that may have nothing to do with the one being tested. The interval on the report can be a document about a different country.
— C. Bąkowski, Łódź
This is correct, common, and something we should have stated. We have added it, and it strengthens rather than weakens the argument for within-person comparison.
On “Which results are findings and which are consequences of the weight loss” — Patient Notes, 7 Mar 2025
You give the reference change value for ALT as about sixty per cent, which strikes me as so large as to make routine monitoring of it pointless. Is that your position?
— D. Sakamoto, Kobe
Not quite. It makes monitoring for small movements pointless, which is different. A doubling is well outside the RCV and is a real signal; a rise from 28 to 41 is not. The value of the test lies in detecting the former, and much of the anxiety it generates comes from acting on the latter.
On “Which results are findings and which are consequences of the weight loss” — Patient Notes, 7 Mar 2025
My eGFR has risen from 71 to 84 over fourteen months of treatment and I have lost twenty-six kilograms. My prescriber described this as the drug protecting my kidneys. Having read your creatinine section, I suspect it is mostly that I have less muscle. Which of us is right?
— R. Ekwueme, Awka
On the information given, probably you, at least in part. A rise of that size during weight loss of that magnitude is well within what reduced creatinine production can produce. A cystatin C-based estimate alongside the creatinine one would separate the two, and is the measurement worth asking for. It is also possible both things are happening.
On “Which results are findings and which are consequences of the weight loss” — Patient Notes, 7 Mar 2025
I stopped treatment fifteen weeks ago and my panel is worse than I expected. I had a panel at five weeks that looked fine and I had assumed I had escaped. Your point about the twelve-week timing was the explanation nobody offered me.
— A. Kirkbride, Leeds
On “Which results are findings and which are consequences of the weight loss” — Patient Notes, 7 Mar 2025
My ferritin fell from 118 to 34 across a year on treatment and I was told this was expected because inflammation had fallen. Six months later I was clearly iron deficient. I appreciate the section on this being ambiguous, but the ambiguity was resolved in one direction and nobody looked.
— P. Hollingsworth, Norwich
That is the failure mode the ambiguity produces, and it is the reason a transferrin saturation alongside costs almost nothing and resolves the question. We are sorry it went that way.
On “What a split-sample exercise can establish, and what it cannot” — The Ledger, 7 Mar 2025
On the archive point: a public record of submissions by vendor would be gamed within a month. Vendors would submit under the names of resellers, or through intermediaries, and the archive would show a distribution as selected as the current one but with a veneer of completeness.
— H. Okwuosa, Enugu
Probably true in part, and it is the strongest argument against our proposal. Our answer is that gaming requires effort and leaves traces, which the present arrangement does not, and that a partially gamed record is more informative than no record. We would not claim more than that.
On “What a split-sample exercise can establish, and what it cannot” — The Ledger, 7 Mar 2025
VendorInvestigate does not measure anything and you have grouped it with three laboratories under the heading independent testing. That is exactly the conflation your article says the market makes.
— E. Vandenberghe, Ghent
A fair hit. The tag under which this coverage sits predates the distinction we now draw, and we have added the distinction to the second paragraph and to the table. The department name will follow at the next reorganisation of the site.
On “What a split-sample exercise can establish, and what it cannot” — The Ledger, 7 Mar 2025
The price table is the most useful thing you have published this year and also the thing most likely to be quoted out of context by somebody selling a comparison service. You might consider a note.
— N. Bujanović, Sarajevo
There is one, and we have strengthened it. The figures are what this publication was invoiced at list rates and are not quotations a reader should expect; volume submitters pay materially less.
On “What a split-sample exercise can establish, and what it cannot” — The Ledger, 7 Mar 2025
You note that no service offers sterility testing and that it takes fourteen days. Worth saying more plainly: a purity certificate and a sterility assurance are not merely different tests, they are different disciplines with different facilities, and no amount of chromatography will ever bear on it.
— S. Tovmasyan, Gyumri
Correct and worth the emphasis. We have said it in the certificates piece and should say it here too: nothing any of these four services sells addresses sterility, endotoxin or container closure integrity, and no combination of their reports adds up to one.
On “What a split-sample exercise can establish, and what it cannot” — The Ledger, 7 Mar 2025
You disclose that two of these services advertise with you and then spend four thousand words on structural criticism of the sector they operate in. I cannot decide whether that is admirable independence or an elaborate way of appearing independent. Probably the former. I wanted to say that I noticed the question.
— B. Osei-Bonsu, Kumasi
So do we, every time this department writes about the sector. The only answers we have are procedural: the disclosure, the standards desk edit, the consulting prohibition on the writer, and the practice of printing objections like yours unedited.
On “When a better instrument changes the answer rather than the confidence” — Analytics, 6 Mar 2025
I have spent a week trying to reconcile a certificate’s stated mass of 4113.6 with a figure of 4111.1 I calculated from the sequence, and had convinced myself something was wrong with the vial. It was the isotope convention. Thank you, and also: how is this not stated on every certificate in existence?
— V. Petrosyan, Yerevan
We wish we knew. It is the single most common source of spurious discrepancies reaching this desk, it costs nothing to state, and we have now asked all twenty companies in the dossier programme to add it. Three have.
On “When a better instrument changes the answer rather than the confidence” — Analytics, 6 Mar 2025
You write that leucine and isoleucine cannot be distinguished by tandem mass spectrometry. That is too absolute. Side-chain fragmentation under high-energy conditions produces diagnostic w and d ions, and the discrimination has been demonstrated repeatedly.
— E. Thistlethwaite, Sheffield
Correct, and the text has been amended. The discrimination is achievable under specialised conditions and is not available in any routine service this market uses, which is what we should have written rather than the stronger claim.